Page last updated: 2024-12-08

scymnol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

scymnol: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID165531
CHEBI ID50106
SCHEMBL ID3092941
MeSH IDM0201052

Synonyms (14)

Synonym
CHEBI:50106
(24r)-5beta-cholestane-3alpha,7alpha,12alpha,24,26,27-hexol
scymnol
5beta-scymnol
6785-34-8
5beta-cholestane-3alpha,7alpha,12alpha,24,26,27-hexol
cholestane-3,7,12,24,26,27-hexol, (3alpha,5beta,7alpha,12alpha)-
5-BETA-SCYMNOL
(3r,5s,7r,8r,9s,10s,12s,13r,14s,17r)-17-[(2r,5r)-5,7-dihydroxy-6-(hydroxymethyl)heptan-2-yl]-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthrene-3,7,12-triol
LMST04030173
SCHEMBL3092941
cholestane-3,7,12,24,26,27-hexol
DTXSID10987196
Q27121907

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Exposure of healthy male Swiss mice to a toxic overdose of APAP (350 mg/kg, ip) significantly increased serum hepatocellular enzyme activities, decreased hepatocellular glutathione (GSH) levels, and induced severe centrilobular hepatocellular necrosis."( Elucidation of the hepatoprotective moiety of 5β-scymnol that suppresses paracetamol toxicity in mice.
Carter, F; Hodges, LD; Kalafatis, N; Macrides, TA; Wright, PF, 2016
)
0.69
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (6)

ClassDescription
3alpha-hydroxy steroidA 3-hydroxy steroid in which the 3-hydroxy substituent is in the alpha-position.
7alpha-hydroxy steroidA 7-hydroxy steroid in which the hydroxy group at position 7 has an alpha-configuration.
12alpha-hydroxy steroid
24-hydroxy steroid
26-hydroxy steroidAny hydroxy steroid in which a hydroxy group is located at position 26.
27-hydroxy steroid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (7.14)18.7374
1990's7 (50.00)18.2507
2000's2 (14.29)29.6817
2010's3 (21.43)24.3611
2020's1 (7.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.41 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index5.49 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]